Canopy GrowthHAM:11L -0.74%59 Days Inventory is 155.13 as of Mar. 2026, which is 26% below its 10-year median of 211.03. GuruFocus rates HAM:11L with a GF Score™ of 59/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 919 Drug Manufacturers companies, Canopy Growth ranks worse than 53.21% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Canopy Growth's Average Total Inventories for the
three
months ended in Mar. 2026 was €67.5 Mil. Canopy Growth's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €39.7 Mil.
Hence, Canopy Growth's Days Inventory for the
three
months ended in Mar. 2026 was 155.13.
The historical rank and industry rank for Canopy Growth's Days Inventory or its related term are showing as below:
HAM:11L'
s Days Inventory Range Over the Past 10 Years
Min: 132.36 Med: 211.03 Max: 10528.75
Current: 172.75
During the past 13 years, Canopy Growth's highest Days Inventory was 10528.75. The lowest was 132.36. And the median was 211.03.
HAM:11L's Days Inventory is ranked worse than 53.21% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs HAM:11L: 172.75
Canopy Growth's Days Inventory
declined
from Mar. 2025 (159.76) to Mar. 2026 (155.13).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Canopy Growth's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Canopy Growth's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.50.
Canopy Growth (HAM:11L) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Canopy Growth's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Canopy Growth's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Canopy Growth Days Inventory Related Terms
Canopy Growth Days Inventory Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Days Inventory distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (HAM:11L) has a Days Inventory of 155.13 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Canopy Growth and its competitors. This is 26% below median its historical median of 211.03. Over the past decade, Canopy Growth's Days Inventory has ranged from 132.36 to 10,528.75. According to the industry distribution chart, Canopy Growth ranks #489 out of 919 companies in the Drug Manufacturers industry, placing it in the top 53.2%.
Is Canopy Growth's Days Inventory too high?
Canopy Growth's current Days Inventory of 155.13 is 26% below median its 10-year median of 211.03. Over the past 10 years, this metric has ranged from a low of 132.36 to a high of 10,528.75. The Drug Manufacturers industry median Days Inventory is 164.48. Canopy Growth's value of 155.13 is 5.7% below this industry median. Based on the distribution chart, Canopy Growth ranks #489 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Canopy Growth has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #489 out of 919 companies for Days Inventory. This places Canopy Growth in the lower half of its industry. The industry median Days Inventory is 164.48. Canopy Growth's value of 155.13 is 5.7% below this benchmark. Historically, Canopy Growth's own Days Inventory has ranged from 132.36 to 10,528.75 over the past decade. While the company's 10-year median is 211.03 vs. the industry median of 164.48, Canopy Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canopy Growth's current Days Inventory of 155.13 is 5.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Canopy Growth and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Days Inventory is 155.13, which is 26% below median its own 10-year median of 211.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (HAM:11L) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €0.84 — trading 30.7% above its estimated fair value. The current Days Inventory is 155.13, which is 26% below median its 10-year median of 211.03 and 5.7% below the Drug Manufacturers industry median of 164.48. Canopy Growth's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Canopy Growth (HAM:11L), the current Days Inventory is 155.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (HAM:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.84 is trading 30.7% above its estimated GF Value™ of €0.64.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for HAM:11L:
Days Inventory: 155.13 (26% below median its 10-year median of 211.03)
GF Value™: €0.64 vs. price of €0.84 (30.7% above fair value)
Industry Position: 5.7% below the Drug Manufacturers median (#489 of 919)
No single metric tells the full story. See the HAM:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
59GF Score
Get the complete analysis for HAM:11L
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:11L has been successfully added to your 
